DANISH Trial – ICD Subgroup Mortality Index

Clinical calculation support · Verify results before clinical use

Educational summary of selected subgroup findings from the DANISH trial for primary-prevention ICD therapy in non-ischaemic systolic heart failure. Enter the patient profile to see whether it matches the age and NT-proBNP thresholds explored in subgroup analyses.

Patient profile

Complete all fields. CRT and NYHA class are recorded for context and do not alter the subgroup classification.

2 markersExploratory
Subgroup threshold: ≤70 years.
Trial median: 1,177 pg/mL; this is a study subgroup cut point, not a treatment threshold.
Reset

Clinical context and interpretation

The DANISH trial evaluated primary-prevention ICD implantation in patients with non-ischaemic systolic heart failure. In the main trial, ICD implantation did not significantly reduce all-cause mortality overall, although sudden cardiac death was reduced.

What the subgroup markers mean

  • Age: a prespecified subgroup analysis reported an association between ICD and lower all-cause mortality in patients aged ≤70 years (HR 0.70, 95% CI 0.51–0.96), but not in older patients.
  • NT-proBNP: in extended follow-up, the estimate below the median was HR 0.75 (95% CI 0.55–1.03); the interaction test was not statistically significant.
  • CRT: CRT status is displayed as context only. It does not change this tool's classification.

Clinical use

This tool classifies whether entered values match two published subgroup cut points. It does not calculate absolute mortality risk, predict an individual treatment effect, or determine ICD eligibility. Decisions require current guideline criteria, expected survival, comorbidity, competing risks, patient preferences, and specialist assessment.

Key evidence

Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375:1221–1230. doi:10.1056/NEJMoa1608029
Elming MB, Nielsen JC, Haarbo J, et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation. 2017;136:1772–1780. doi:10.1161/CIRCULATIONAHA.117.028829
Butt JH, Yafasova A, Elming MB, et al. NT-proBNP and ICD in Nonischemic Systolic Heart Failure: Extended Follow-Up of the DANISH Trial. JACC Heart Fail. 2022;10:161–171. doi:10.1016/j.jchf.2022.01.003
Clinical disclaimer: Educational use only. This is not a validated risk score or decision rule. Subgroup findings may be exploratory and should not be interpreted as proof of benefit or lack of benefit for an individual patient. Do not use this tool as a substitute for guideline-based assessment or shared decision-making.